Oyster Point Pharma Goes Public

Oyster Point Pharma is now officially listed on the Nasdaq Global Market under “OYST.” Initial share pricing was $16; to date the stock’s high has been $19.01, while its low has been $15.16. Look for Oyster Point to join the OIS Index in the next report.

Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.